192 related articles for article (PubMed ID: 28279521)
1. Recombinant Human ACE2 and the Angiotensin 1-7 Axis as Potential New Therapies for Heart Failure.
Patel VB; Lezutekong JN; Chen X; Oudit GY
Can J Cardiol; 2017 Jul; 33(7):943-946. PubMed ID: 28279521
[TBL] [Abstract][Full Text] [Related]
2. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.
Patel VB; Zhong JC; Grant MB; Oudit GY
Circ Res; 2016 Apr; 118(8):1313-26. PubMed ID: 27081112
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases.
Parajuli N; Ramprasath T; Patel VB; Wang W; Putko B; Mori J; Oudit GY
Can J Physiol Pharmacol; 2014 Jul; 92(7):558-65. PubMed ID: 24861775
[TBL] [Abstract][Full Text] [Related]
4. ACE2 of the heart: From angiotensin I to angiotensin (1-7).
Keidar S; Kaplan M; Gamliel-Lazarovich A
Cardiovasc Res; 2007 Feb; 73(3):463-9. PubMed ID: 17049503
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.
Oudit GY; Penninger JM
Curr Heart Fail Rep; 2011 Sep; 8(3):176-83. PubMed ID: 21611889
[TBL] [Abstract][Full Text] [Related]
6. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
Mori J; Zhang L; Oudit GY; Lopaschuk GD
J Mol Cell Cardiol; 2013 Oct; 63():98-106. PubMed ID: 23886814
[TBL] [Abstract][Full Text] [Related]
7. [Role of ACE2-Ang (1-7)-Mas receptor axis in heart failure with preserved ejection fraction with hypertension].
Yu J; Wu Y; Zhang Y; Zhang L; Ma Q; Luo X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):738-746. PubMed ID: 30124209
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2.
Patel VB; Takawale A; Ramprasath T; Das SK; Basu R; Grant MB; Hall DA; Kassiri Z; Oudit GY
J Mol Med (Berl); 2015 Sep; 93(9):1003-13. PubMed ID: 25874965
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment.
Kittana N
Fundam Clin Pharmacol; 2018 Feb; 32(1):14-25. PubMed ID: 28833476
[TBL] [Abstract][Full Text] [Related]
10. Role of ACE2 in diastolic and systolic heart failure.
Wang W; Bodiga S; Das SK; Lo J; Patel V; Oudit GY
Heart Fail Rev; 2012 Sep; 17(4-5):683-91. PubMed ID: 21638102
[TBL] [Abstract][Full Text] [Related]
11. Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats.
Husková Z; Kopkan L; Červenková L; Doleželová Š; Vaňourková Z; Škaroupková P; Nishiyama A; Kompanowska-Jezierska E; Sadowski J; Kramer HJ; Červenka L
Clin Exp Pharmacol Physiol; 2016 Apr; 43(4):438-49. PubMed ID: 26833491
[TBL] [Abstract][Full Text] [Related]
12. ACE2: a new target for cardiovascular disease therapeutics.
Raizada MK; Ferreira AJ
J Cardiovasc Pharmacol; 2007 Aug; 50(2):112-9. PubMed ID: 17703127
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS.
Patel VB; Clarke N; Wang Z; Fan D; Parajuli N; Basu R; Putko B; Kassiri Z; Turner AJ; Oudit GY
J Mol Cell Cardiol; 2014 Jan; 66():167-76. PubMed ID: 24332999
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats.
Awwad ZM; El-Ganainy SO; ElMallah AI; Khattab MM; El-Khatib AS
Toxicology; 2019 Dec; 428():152310. PubMed ID: 31629013
[TBL] [Abstract][Full Text] [Related]
15. [Regulation of angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis provides a new target for the treatment of cardiac remodeling and heart failure].
Yang L; Huang Y; He Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Nov; 31(11):1425-1428. PubMed ID: 31898578
[TBL] [Abstract][Full Text] [Related]
16. Activation pattern of ACE2/Ang-(1-7) and ACE/Ang II pathway in course of heart failure assessed by multiparametric MRI in vivo in Tgαq*44 mice.
Tyrankiewicz U; Olkowicz M; Skórka T; Jablonska M; Orzylowska A; Bar A; Gonet M; Berkowicz P; Jasinski K; Zoladz JA; Smolenski RT; Chlopicki S
J Appl Physiol (1985); 2018 Jan; 124(1):52-65. PubMed ID: 28970203
[TBL] [Abstract][Full Text] [Related]
17. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-(1-7): beyond the cardio-renal actions.
Passos-Silva DG; Verano-Braga T; Santos RA
Clin Sci (Lond); 2013 Apr; 124(7):443-56. PubMed ID: 23249272
[TBL] [Abstract][Full Text] [Related]
19. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases.
Moreira de Macêdo S; Guimarães TA; Feltenberger JD; Sousa Santos SH
Peptides; 2014 Dec; 62():189-96. PubMed ID: 25453980
[TBL] [Abstract][Full Text] [Related]
20. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis.
Simões E Silva AC; Teixeira MM
Pharmacol Res; 2016 May; 107():154-162. PubMed ID: 26995300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
